WuXi Biologics (2269.HK), a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has recently inked a research service agreement with BioNTech SE (Nasdaq: BNTX), a leading immunotherapy company specializing in innovative treatments for cancer and other severe illnesses.

Per the terms of the agreement, WuXi Biologics will employ its proprietary antibody discovery technology platforms within its Research Service Unit to identify two undisclosed targets for preclinical investigational monoclonal antibodies. These antibodies will be developed by BioNTech as next-generation therapeutic product candidates. In exchange for granting exclusive rights to these investigational monoclonal antibodies, WuXi Biologics will receive an upfront payment of $20 million. Additionally, the company is entitled to potential future payments, including those related to research, development, regulatory milestones, commercialization, and tiered royalties.

Dr. Chris Chen, CEO of WuXi Biologics, expressed satisfaction with their CRDMO model's success and highlighted the significance of supporting BioNTech's innovative pipeline. He emphasized the agreement as a testament to WuXi Biologics' leadership in discovery service solutions and its capability to provide integrated technology platforms for global partners in developing new therapeutic modalities. The collaboration aims to contribute to the development of potential therapeutics with enhanced outcomes for patients worldwide.

WuXi Biologics offers a comprehensive range of end-to-end and modular discovery services, covering the entire process from idea to the identification of preclinical candidates. The company employs industry-leading technology platforms for generating, characterizing, engineering, optimizing, and selecting novel antibody and biologic therapeutics. These platforms include hybridoma technology, single B cell cloning technology, phage display and yeast display technology, immune and synthetic human scFv and VHH libraries, human IgG transgenic platforms, WuXiBody™ and SDarBody™ bispecific/multispecific antibody platforms, and other antibody and biologics generation and optimization technologies. All these technology platforms are supported by WuXi Biologics' extensive capabilities in research material generation and assay development.

 

Source: wuxibiologics.com

Report Abuse